Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish kroner), missing the consensus of $11.79 billion.
Sales increased by 13% in Danish kroner and 18% at CER, driven by increased sales across the portfolio. GLP-1 diabetes sales increased by 8% to 38.37 billion Danish kroner, and Obesity care sales increased by 53% to 20.37 billion Danish kroner.
Insulin sales increased by 5% to 12.75 billion Danish kroner, and Rare disease sales increased by 28% to 4.92 billion Danish kroner.
The weight loss drug maker reported earnings of 91 cents per share (5.96 Danish kroner), missing the consensus of 93 cents.
Ozempic sales increased 15% to 31.79 billion Danish kroner, and Wegovy sales jumped 75% to 19.53 billion Danish kroner.
Outlook
In July, Novo Nordisk shared its trimmed 2025 outlook. The company reiterated the lowered guidance on Wednesday with sales growth of 8-14% at CER, and operating profit growth of 10-16% at CER.
The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025, reflecting the persistent use of compounded GLP-1s, slower-than-expected market expansion, and competition.
Lars Fruergaard Jørgensen, president and CEO, said, “While delivering 18% sales growth in the first half of 2025, we have …